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ABSTRACT
Genomic Instability in Severe Congenital Neutropenia, a Leukemia Predisposition
Syndrome

By Adya Sapra, B.Tech
A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science Virginia Commonwealth University.

Virginia Commonwealth University, 2018

Director: Seth Corey, MD, MPH
Professor, Department of Pediatrics
Department of Human and Molecular Genetics
Virginia Commonwealth University

Severe congenital neutropenia (SCN) is a rare blood disorder characterized by abnormally
low levels of circulating neutrophils. Mutations in multiple genes like neutrophil elastase gene
(ELANE) and granulocyte colony stimulating factor receptor (CSF3R) may cause SCN. The
treatment of choice for SCN is the administration of granulocyte-colony stimulating factor (G-CSF)
which elevates the neutrophil count and hence improves the survival and quality of life. Long term
survivorship on G-CSF is however linked to development of MDS (myelodysplastic
syndrome)/AML (acute myeloid leukemia). About 70% of MDS/AML patients acquire nonsense
mutations affecting the cytoplasmic domain of CSF3R. In this project, we hypothesized that this
coding region of CSF3R constitutes a hotspot, vulnerable to mutations resulting from excessive
oxidative stress or endoplasmic reticulum (ER) stress. We used the murine Ba/F3 cell line to study
the effect of induced oxidative or ER stress on the mutation rate in our hypothesized hotspot of the

x

exogenous human CSF3R, the corresponding region in the endogenous Csf3r, and a leukemiaassociated gene Runx1. Ba/F3 cells transduced with the cDNA for partial C-terminal of CSF3R fused
in-frame with a Green Fluorescent Protein (GFP) tag was subjected to cellular stress inducing
mutagen treatment for a prolonged period of time (30 days). The amplicon based targeted deep
sequencing data for days 15 and 30 samples show that although there was increased mutagenesis
observed in all genes, there were more mutations in the GFP region as compared to the GC-rich
partial CSF3R region. Our findings also indicate that there is no correlation between the stressinducing chemical treatments and mutagenesis in Ba/F3 cells. Thus, we conclude that there are other
mechanisms to acquired mutations of CSF3R that help drive the evolution of SCN to MDS/AML.
To test this hypothesis, further experiments using unique barcoding system are in progress to
characterize the clonal competition between different mutant CSF3R and ELANE expressing cell
lines. This study will shed further light on the selection advantage that is provided to cells because
cooperativity between mutations in different genes.

.
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CHAPTER 1
INTRODUCTION

Severe Congenital Neutropenia: a leukemia predisposition syndrome
Background: Severe Congenital Neutropenia (SCN) is a genetically heterogeneous condition
characterized by pathologically low levels of neutrophils. This disorder was first described in 1950
by Rolf Kostmann, who coined the name infantile genetic agranulocytosis to this disease1. In his
doctoral thesis published in 1956, Kostmann described the clinical and histologic course of SCN in
14 patients, belonging to 9 consanguineous families from Northern Sweden. He also observed the
heterogeneity in the genotype and phenotype of SCN1–3. In 1970, SCN was first identified as a preleukemic syndrome.
As part of the innate immune system, neutrophils provide the first line of defense against
microbes by secreting several antimicrobial peptides that can modulate the cytokine and chemokine
networks. Thus, neutrophils are critically responsible for providing an early response in both killing
antigens and reconstituting tissue integrity2,4,5. Clinically significant neutropenia, which can cause
an individual immunocompromised is diagnosed when the peripheral absolute neutrophil count
(ANC) is lower than 1500/µl. SCN is defined as ANC of less than 500/µl3. Patients with SCN are
prone to life-threatening, recurrent bacterial infections such as otitis media, bronchitis, pneumonia,
osteomyelitis, or cellulitis. Many SCN patients have been also diagnosed with chronic gingivitis
and tooth decay. In addition, decreased bone mineral density, leading to ostopenia or osteoporosis
and increased propensity to fractionation, are other common clinical problems associated with
SCN3. Clinical diagnosis of SCN includes examination of bone marrow for accumulation of early
myeloid precursors. SCN patients show maturation arrest in the early stages of neutrophil
1

development in the bone marrow which leads to accumulation of undifferentiated myelocytic
progenitors (Figure 1).

Molecular Genetics of SCN
Mutations in multiple genes have been implicated in SCN. These include the neutrophil
elastase (ELANE), mitochondrial-associated protein HAX1, transcription factor GFI1, metabolic
enzyme G6PC, granulocyte colony stimulator factor receptor CSF3R, and Wiskott-Aldrich
syndrome protein WAS.
The most frequent mutations in SCN patients involve ELANE and are found in
approximately 40% of the patients. To date, more than 100 mutations have been identified in
ELANE-associated SCN6, which are either transmitted in autosomal dominant pattern or are
spontaneously acquired7,8. The leading hypotheses state that germline ELANE mutations result in
misfolding and/or mislocalization of neutrophil elastase, which triggers the unfolded protein
response (UPR). This highly conserved biological process consists of a collection of intracellular
signal transduction pathways which are activated in response to endoplasmic reticulum (ER) stress.
UPR is initiated via 3 pathways localised in the ER: IRE1alpha (inositol-requiring 1alpha), PERK
(double-stranded RNA-dependent protein kinase [PKR]–like ER kinase), and activating
transcription factor 6 (ATF6). In case of excessive ER stress, these signals pathways get activated
in order to maintain homeostasis in the cell. In case of all three UPR mechanisms fail, UPR then
promotes apoptosis of the cell. Thus, UPR, activated due to ER stress, causes apoptosis of
differentiating neutrophil precursors at the promyelocyte stage, leading to accumulation of
promyelocytic progenitors and subsequent deficiency of mature neutrophils9. Thus, SCN is
associated with both germline and spontaneous ELANE mutations. Germline ELANE mutations in
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SCN are further associated with spontaneous acquired CSF3R mutations, which may have a role in
the evolution of SCN to AML.

Treatment of SCN
The most important therapeutic goal in patients with SCN is the reconstitution of adequate
antibacterial host defense by increasing neutrophil numbers. Marrow cells from SCN patients
display a reduced responsiveness to granulocyte-colony-stimulating factor (G-CSF). The first line
of treatment of choice for SCN is the administration of recombinant human G-CSF which binds to
and activates a specific receptor (CSF3R) which further transduces signals critical for the
proliferation and maturation of granulocytic progenitor cells. G-CSF treatment increases the
neutrophil count, helps resolve pre-existing infections, diminishes the number of new infections,
and significantly improves the survival and quality of life10.
Although G-CSF successfully induces proliferation, differentiation and survival of myeloid
progenitors, however, long term survival with G-CSF is linked to the development of
myelodysplastic syndrome/acute myeloid leukemia (MDS/AML). Approximately 30% of SCN
patients undergoing G-CSF treatment develop AML or MDS6,10,11. Interestingly, about 70% of SCN
patients with MDS/AML acquire nonsense mutations in the region of CSF3R that encodes the
cytoplasmic domain. Originally, it was believed the main cause of SCN is germline mutations in
CSF3R12. However, subsequent studies13,14 indicate that the CSF3R mutations that have been found
in previous SCN patients were somatic or de novo in meiosis, rather than being germline in nature.
These non-inherited CSF3R mutations are generally characterized by a truncation variant, usually
found in the C-terminal of the CSF3R, and are associated with a hyperproliferative phenotype in the
mutated cells observed in the leukemogenic events seen with SCN4,11.
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Clonal Evolution of SCN to MDS/AML: Literature Review
Previous studies on SCN patients have shown that initial driver mutations involve CSF3R,
and cell clones harboring CSF3R mutations have a growth advantage and acquire additional
cooperating mutations that contribute to AML initiation and disease progression4,5. As reported by
Skakova et al5 out of 31 SCN patients who developed MDS/AML, 81% patients (23) had acquired
CSF3R mutations and 65% patients (20) had mutations in RUNX1. Furthermore, 17 patients had
mutations in both CSF3R and RUNX1. Another interesting observation was that all the 6 patients
who were negative of both RUNX1 and CSF3R mutations developed only MDS, as compared to the
group of 17 patients with cooperative CSF3R and RUNX1 mutations, out of which 11 developed
AML and 6 developed MDS/AML. Thus, a high frequency of cooperativity between CSF3R and
RUNX1 mutations occurs in the transformation of SCN to AML. In another clinical study5 by the
same group, the mutational landscape of one SCN patient under G-CSF therapy who developed
AML was done. The sequencing results showed that the CSF3R mutations were observed at an
initial onset of SCN and RUNX1 mutations were observed just a few months prior to onset of AML.
Furthermore, both CSF3R and RUNX1 mutations diminished immediately after the G-CSF
treatment was stopped temporarily and the mutations re-emerged after the treatment was restarted5.
These studies suggest that G-CSF treatment is directly linked with increased mutagenesis which
leads to development of MDS/AML in SCN patients. Also, mutations in different genes work in
cooperativity to provide the clonal advantage to cells.
More than 70% of SCN patients who developed MDS/AML had mutations in the
cytoplasmic domain of CSF3R11. In the most comprehensive study to date, Germeshauisen et al
analyzed the genomic data of 218 patients with congenital neutropenia to determine the incidence
of frequently mutated sites in CSF3R associated with the development of MDS/AML. Nonsense
mutations in seventeen different nucleotide positions in the CSF3R intracellular domain, leading to
truncation of one to four tyrosine residues, were identified. Incidentally, all of these mutations were
4

present in the cytoplasmic domain of the CSF3R. Since, this region of the cytoplasmic domain was
most highly mutated, we have transduced this specific region in our cell line models for our
mutagenesis study. The seventeen most frequently mutated nucleotide positions in CSF3R as
detected by Germeshausen et al. are shown in Figure 2. The mutations that were detected most
frequently in patients with SCN were truncation mutations affecting glutamine at the following
amino acid positions: d739, d741, d749 and d754 (d715, d717, d725 and d730 respectively,
according to the old nomenclature, which excludes 24 amino acids of the signal peptide region).
Other less frequent mutations included truncation mutations in glutamine (725, 730, 743, 759 and
774), tyrosine (727, 752, 767 and 787), arginine (734) and Lysine (785); frameshift mutation in
Serine (747); and deletion of 10 bp (2848-2857). These nucleotide changes are represented in Figure
3.
We hypothesize that this region corresponding to the cytoplasmic domain of CSF3R
constitutes a mutational hotspot. This vulnerability to mutations may result from excessive oxidative
or ER stress. In SCN, myeloid precursors are under stress due to cellular responses like UPR. Under
stress conditions, reactive oxidation species (ROS) production increases, and G-CSF treatment can
lead to a further increase in ROS production. Thus, the combination of stress pathways and the GCSFR-mediated signaling transduction pathways creates an environment of enhanced oxidative
stress, which may promote genomic instability. This study is focused on determining the mutation
rate of cytoplasmic domain of CSF3R under conditions of ROS and UPR stress (Aim 1).

Molecular biology of mutagenesis and mutation hotspots
Mutagenesis is the process of introducing permanent alterations, called mutations, in the
sequence of DNA, that might cause genetic instability. These mutations can affect a single base pair
to a large segment of a chromosome that includes multiple genes. The mutations in genomic DNA
5

can be classified into the following groups and subgroups: point mutations (transitions and
transversions), deletions/insertions, duplications, inversions, and chromosomal rearrangements.
Point mutations are single base-pair substitutions that can be further classified in the following
subgroups: silent mutations (single nucleotide substitutions that do not change the amino acid after
translation); missense mutations (single nucleotide substitutions that can change the amino acid
coded during translation); nonsense mutations (premature stop codon substitution) and frameshift
mutations (insertion or deletion of nucleotides causing change in the reading frame of the cDNA).
Transition mutations occur when either a purine (A,G) mutates to the other purine or a pyrimidine
(C,T) mutates to the other pyrimidine. Transversion mutations are substitution of purines with
pyrimidines and vice versa15. Complex mutations are rare mutations that consist of combinations of
several point mutations. Point mutations are often a direct result of mutagenesis whereas genetic
recombination causes other types of mutations like chromosomal rearrangement15–18.
Mutations can be inherited (germline) or acquired (somatic). As mentioned earlier, SCN is
known to be caused due to germline mutations in various genes like ELANE and HAX1. These
mutations can be inherited in an autosomal dominant or recessive manner. Recessive mutations lead
to loss of function, whereas dominant mutations often, but not always, result in gain of function 19.
Acquired mutations, on the other hand, occur spontaneously in certain somatic cells, and unlike
germline mutations, are not present ubiquitously. These mutations can be induced, i.e. caused due
to external factors like ultraviolet radiations or chemical mutagens; or spontaneous, i.e. can occur
due to errors during DNA replication, recombination or repair, or due to endogenous DNA
damage20,21.
There are two different classes of mutagenic mechanisms: directly induced base mispairing
and misrepair. Spontaneous or induced mispairing can lead to specific base-pair substitutions21.
Mispairing can occur in various ways. Tautomerization of bases often leads to “mistaken”
mispairing. The keto form of each base is normally found in DNA, whereas the enol forms of the
6

bases are rare. The complementary base pairing of the enols is different from that of the keto forms.
For example, as shown in Figure 4, during replication, guanine changes to its enol form, which binds
to an incoming thymine instead of its pair cytosine. This mispairing thus leads to an AT mutation
instead of GC in the next round of replication22. Mispairing also occurs when different bases are
ionized simultaneously. 5- Bromouracil (5-BU) and 2-aminopurine (2-AP) are base analogs that can
induce mutagenesis. 5-BU is an analog of thymine that can be mistakenly incorporated into DNA
as a base. In its normal keto state, 5-BU mimics the pairing behavior of the thymine that it replaces,
pairing with adenine. The presence of the bromine atom, however, causes a relatively frequent
redistribution of electrons, so 5-BU can spend part of its existence in the rare ionized form. In this
state, it pairs with guanine, mimicking the behavior of cytosine and thus inducing mutations in
replication23. Similarly, 2-AP, an analog of adenine, pairs with thymine, but when protonated, it can
mispair with cytosine, thereby inducing mutations during replication. Alkylating agents, such as
ethyl methanesulfonate (EMS) and nitrosoguanidine (NG), alter the nucleotide bases, thus causing
specific mispairing. For example, EMS-generated ethylation causes alkylation of O-6 position of
guanine and O-4 position of thymine, that can lead to direct mispairing of these bases. Another
common cause of spontaneous mutation due to misparing is the deamination of cytosine to uracil in
the DNA double helix. This leads to the replacement of the wild-type GC base pair with a TA base
pair in the subsequent daughter cells24. Thus, regions that have higher GC content are more prone
to mutagenesis and usually can be considered as mutational hotspots. Another mechanism of
inducing mutagenesis is misrepair mutagenesis, which can be inferred either directly, by obtaining
appropriate repair defective mutants, or indirectly, by ultraviolet (UV) and ionization radiation25.
Mutation frequency can vary significantly along nucleotide sequences, often leading to the
concentration of maximum mutations in certain positions, which are known as mutational
‘hotspots’26. The question that arises here is that what makes certain regions in the DNA more prone
to mutagenesis? Several studies have been done to answer this question27–31. Mutational hotspots
7

reflect specific mechanisms of clustering of mutations in specific regions. Thus, to study mechanism
of mutagenesis and their effects on the functional domains of target proteins, it is of outmost
importance to study mutation hotspots.

Serial acquisition and cooperativity of mutations in clonal hematopoiesis
Previous clinical and experimental studies have indicated that different mutations work in
cooperativity to provide a clonal advantage to the cells. Beekman et al. in 2012 identified early and
late genetic effects associated with leukemic progression in one SCN patient. Germline ELANE
mutation was detected soon after birth. During the early stages of SCN, four mutations in CSF3R
(d715 accompanied by LLGL2 mutation; d717; d7125 and d730) arose. However, as SCN
progressed towards AML, only one clone containing CSF3R d715 mutations was able to proliferate.
This study suggests that additional mutations in LLGL2 and ZC3H18 acquired during the
progression of SCN to AML provided a selective proliferative advantage to the cells. It can be
concluded from this study that remaining three clones were probably unable to survive because of
lack of additional cooperating mutations that were present in case of d715 mutations. It is unclear if
mutations in specific genes can cooperate with each other to provide the cells with selection
advantage. The second part of our study focuses on answering this question by studying the clonal
competition between different CSF3R and ELANE-expressing cell lines. We hypothesize that the
mutant CSF3R and ELANE will provide a selective advantage to the cells (Aim 2). We will
investigate the proliferative advantage of different CSF3R and ELANE mutant expressing cell lines
using unique barcoding system which can be detected by Next Generation Sequencing Analysis
(NGS).
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CHAPTER 2
MATERIALS AND METHODS

Cells and Culture Conditions
Ba/f3 cells were obtained from ATCC and grown and maintained in 1X RPMI-1640 medium
(CellGro) which was supplemented by 10% Fetal Bovine Serum (FBS), 1% PenStrep, 1X Glutamax
and 2ng/ml mIL3. The cells were passaged every 11/2 days and the cell density was maintained
between 1x105 (lower limit) and 1x106 (upper limit) cells/ml. The cells were maintained and used
for not more than 2 months post thaw date.
Transduction of Ba/F3 cells with Partial C terminal of CSF3R construct
Lentiviral transduction was carried out using the spinoculation procedure to transduce the partial C
terminal of CSF3R fused with a GFP construct (Figure 5) in Ba/f3 Parent cell line. 1-2 million cells
were centrifuged and resuspended in 1 ml of the crude supernatant obtained during viral production
from 293 FT cells. After resuspension, the cells were plated in a 24 well plate and spinoculation was
performed. The cells were centrifuged at 1000 x g four one hour at room temperature. The cells
were then incubated at 37°C for another 4 hours. The supernatant was discarded and fresh media
(containing mIL3) was added. To confirm confection, cells were checked for fluorescence.

Selection of transduced cells
Transduction was confirmed using FACS, and GFP positive cells were sorted. To select cells, the
cells were incubated in the LD100 dose of the antibiotic, Zeocin (1000 µg/mL) for 7 days. The
zeocin kill curve was established to calculate the minimum lethal dose of zeocin, i.e. the lowest
concentration of zeocin that can cause cell death (LD100). Freshly harvested cells were incubated
9

in 6 wells of a 24 well plate (around 600,000 cells/well). Serial dilution was used to treat cells in
each well with an increasing Zeocin concentrations: 100, 200, 400, 800, and 1000 µg/ml. Negative
control cells were treated with only DMSO (solvent). Cell counts were performed on day 2, 4, 6 and
8 of treatment. Respective Zeocin concentrations were maintained in fresh media with every
passaging.

Dose response curve for stress inducing chemicals: MTT assay
The dose response was formulated to determine the concentration of the stress inducing drugs,
Thapsigargin and TBHQ, that the cells would be exposed to induce ROS and UPR respectively.
1000 cells were plated in each well of a 96 well plate. The cells were treated with increasing
concentrations of thapsigargin (0, 0.064, 0.32, 1.6, 5, 8, 40, 200, 1000 nM, respectively). The cells
were incubated for 48 hours and then, MTT assay was performed. At the desired time point (48
hours), 10 µL of (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) reagent
was added each well. After 4 hours of incubation at 37°C, 100 µL of MTT detergent was added. The
plate was incubated in dark at room temperature overnight. Absorbance was measured at 545 nm.
LD10 and LD20 were selected as optimum dose of stress inducing treatment for both drugs. The
above steps were repeated with TBHQ treatment.

Flow Cytometry Analysis Measurement of ROS production
200,000 cells were plated in each well of a 6-well plate. The cells were treated with the following
concentrations of Thapsigargin respectively: 0 nM (only DMSO) 1nM, 2nM, 5nM and 10nM and
were incubated for 48 hours. The cells were then treated with CellRox Deep Red Reagent (Thermo
Fisher Scientific) at a final concentration of 5 µM and incubated for 30 minutes at 37°C. The cells
were then washed with HBSS buffer and further treated with MitoSox red Reagent (Thermo Fisher
10

Scientific) for 10 minutes. The cells were washed twice with HBSS and finally suspended in 1ml
media before carrying out Flow cytometry analysis.

q-RT-PCR
qPCR was performed to estimate the levels of different UPR markers (ATF4, ATF6, BiP, CHOP,
XBP1spliced and XBP1unspliced) in Ba/F3 cells treated with different doses UPR inducing chemical,
thapsigargin (1 nM, 2 nM and 5 nM). At each desired time point of the treatment, cell pellets were
collected and RNA was extracted using the Qiagen RNeasy Plus Mini Kit. Cells were lysed with
350 µl of Qiagen lysis buffer, buffer RLT and homogenized by vortexing. The homogenized lysate
was placed in the genomic DNA eliminator spin column and centrifuged at > 8000 x g to separate
the gDNA and RNA. 1 volume of 70% ethanol was added to precipitate the RNA out of the solution.
The solution was then pipetted into a RNeasy Mini spin column and centrifuged. The filter was
washed with buffer RW1 and RPE (twice). After drying the membrane, the RNA was eluted using
50 µl of RNase free water. RNA concentrations were measured using NanoDrop One (Thermo
Scientific). cDNA was synthesized from the extracted RNA using the iScriptTM cDNA Synthesis kit
(Bio-Rad). Quantitative PCR was performed on the StepOnePlusTM Real Time PCR System
(Applied Biosystems, Thermo-Fisher Scientific). For the relative quantification of ATF4, ATF6, BiP,
CHOP and XBP1 expression, Actin was selected as an internal control. Power SYBR Green
(Applied Biosystems, Thermo Fisher) was used as a DNA intercalator dye to monitor amplified
DNA quantification, and real-time quantitative PCR curves were analyzed by StepOne Software
v2.3 (Applied Biosystems) in order to obtain threshold cycle (Ct) values for each sample.
Comparative Ct method was used to calculate the mRNA expression levels for each marker. The
housekeeping gene, Actin expression Ct values were comparable among all experiments. The ddCt
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values were calculated for all samples with respect to housekeeping gene expression values and then
day zero Ct values.

Stress Inducing Chemical Treatment
Treatment was carried out on Ba/F3 transduced cells. Cell pellets were stored at -80°C on day 0 to
serve as control. 1000 cells/well were plated in a 96-well plate using serial dilution. The cells were
then treated with the following stress-inducing treatments: thapsigargin 1 nM and 2 nM, TBHQ 1
nM and 2nM, and control (untreated) samples. Each treatment was done in triplicate. The samples
were frozen down at regular intervals (every time the cells were split), as shown in Figure 6. For
initial screening of mutational landscape, samples from day 0, 15 and 30 (for each treatment) were
sent for sequencing. The remaining samples were stored for future follow-up studies.

Next Generation Sequencing: Library Preparation
Mutational analysis of the genes of interest was performed using a sensitive next-generation
amplicon deep sequencing assay. The samples were sent to the Nucleic Acid Research Facilities at
Virginia Commonwealth University for targeted deep sequencing. For the library preparation,
genomic DNA was first extracted from the frozen pellets of all samples using the Qiagen DNeasy
Blood and Tissue DNA Extraction kit. Targeted deep sequencing was performed using the tailed
amplicon sequencing approach with Illumina MiSeq. The sequencing was carried out in three steps:
First round of PCR’s to amplify region of interest, second round of PCR’s to introduce sequencing
adapters, and finally, subsequent sequencing in forward and reverse direction (Figure 7).
The first step was to amplify the region of interest for each of the samples. Our genes of interest
were: the exogenous CSF3R (transduced construct); endogenous Csf3r (Exon 17) and endogenous
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Runx1. To amplify the DNA, PCR’s were performed using Phusion High-Fidelity PCR Master Mix
with HF Buffer (NEB). Since the cDNA of all the 3 genes of interest was too large to amplify the
whole region together, so the amplification was carried out in segments for each gene. The primers
were designed for overlapping sections in each region of interest.
Each primer contained an overhang adapter sequence next to the locus-specific sequence which
helped in pooling the sequences back. The primers were then optimized by performing
temperature gradient PCR’s for each primer. The primer sequences used for the analysis and the
final annealing temperatures for each primer are given in Appendix Table 6.
Once the amplification was carried out and the sequence size was confirmed using PCR, the
segments for each gene were pooled together and barcodes were introduced for identification
purposes before being sequenced. A pool of 96 samples were sequenced in a single library. The
sequencing was carried out in 2 sets to get approximately 100,000 reads/segment.

Next Generation Sequencing Analysis
The bioinformatic analysis on the targeted deep sequencing data was done by Dr. Roman Jaksik,
Silesian University, Poland. Broad Institute (GATK v4) guidelines were followed for the analysis.
The Illumina Nextera adapter sequences introduced during PCR amplification were first removed
using Trim Galore, which is based on Cutadapt too. The filtered sequences were then aligned against
the respective reference genomes, using BWA-MEM algorithm. The alignment reads that were
bound by primers were then trimmed using the BAMClipper tool. Finally, the variants were
discovered using Mutect2 tool. Day 0 samples were used as reference, to eliminate the mutations
that were already present before the treatment started.
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Statistical Analysis
The statistical analysis of the sequencing data was performed by Sara Biesiadny and Dr. Marek
Kimmel, Department of Statistics, Rice University, Texas. The graphs were plotted using R
statistical software. The data was analyzed to calculate the trend of mutations that were detected
during the treatment period. Comparisons were done between the regions of interest, and between
different treatments. The data was divided into different subsets, one for each gene being sequenced.
For each subset, a histogram of the log (base 10) of the ratio of altered reads over coverage was
developed. Once separated according to days, the median of each subgroup was calculated and
plotted.

Preparation of Barcoded Lentiviral Strains
The barcode sequences were obtained from Dr. David Sabatini’s lab at Whitehead Institute for
Biomedical Research, Cambridge, Massachusetts. Each barcode had a unique 7 base pair sequence
integrated in PlkO.1 vector. An example can be seen in Figure 9 which shows the plasmid map of
barcode 69, integrated in plko.1 vector. The plasmids were then transformed into One ShotTM
STBL3TM chemically competent E.Coli. Approximately 1 ng of barcode DNA was added to 12.5 µl
of competent cells and incubated on ice for 30 minutes. The cells were then subjected to heat shock
(42°C) for 45 seconds. After incubating the cells on ice for 2 minutes, 250 µl of S.O.C. Medium
was added to each vial. The cells were then incubated while shaking at 225 rpm for 1 hour at 37°C.
25-100 µl of each transformation was spread on ampicillin plates and incubated overnight at 37°C.
Individual colonies were then selected and the plasmid DNA was purified using QIAprep Spin
Miniprep Kit (Qiagen). The barcode sequences were confirmed by sanger sequencing (Genewiz).
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Preparation of different mutant CSF3R and ELANE expressing cell lines
Ba/F3 parent cells were divided in 2 sets and transduced with wildtype and G185R ELANE
respectively. Transduction was performed using polybrene. Approximately 5000 cells (in 100 µl
media) were plated in 2 wells of a 96 well plate. The cells were then treated with polybrene at a final
concentration of 2 µg/ml. Wildtype and G185R ELANE viral particles were then added to each
respective set. The cells were centrifuged at 600 x g for 45 minutes to integrate the viral particles
into the cells. The cells were then incubated at 37 °C for 1-2 days. Protein expression was confirmed
using western blotting technique. Once ELANE transduction was confirmed, both wildtype and
mutant ELANE expressing cell lines were further divided into 2 sets. Each cell line was then
transduced with wildtype and d715 CSF3R. the cells were selected using fluorescence-activated cell
sorting (FACS). Finally, each of the 4 cell lines were then transduced with a unique barcoded
lentivirus. Transduced cells were selected by puromycin selection. The cell lines were generated to
have specific combinations of CSF3R and ELANE mutations, as shown in Table 2. Once the cell
lines were prepared, single cells were sorted on a FACS instrument (BD LSRFortessa-X20™) into
a 96 well plate. Live cells were identified by light scatter characteristics, and doublets were excluded
from the analysis. Once the single cell clones were sorted, they were allowed to proliferate, and
finally 3 clones from each barcode induced cell line having similar levels of ELANE and CSF3R
expression were chosen for the experiment.
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CHAPTER 3
RESULTS

Transduction of Ba/F3 Cells
Lentiviral transduction was carried out using the spinoculation procedure to insert the Fused
partial C terminal of CSF3R and mNeon Green region into the Ba/F3 parental cells. Flow cytometry
analysis on the transduced Ba/F3 cells showed the presence of the GFP-negative and GFP-positive
cells. The cells were then subjected to antibiotic selection for the transduced cells. The chosen
antibiotic was zeocin, which belongs to the bleomycin family and is isolated from isolated from
Streptomyces verticillus. It is a basic, water-soluble and copper-chelating glycopeptide, and contains
a phleomycin D1 frame. Once the Once being activated by reducing Cu2+ to Cu1+ in cells, Zeocin
causes double strand breaks (DSBs) of DNA. Prolonged treatment with high non-lethal doses of
zeocin can have a mutagenic effect. Thus, to avoid any additional mutagenesis, the cells were
subjected to selection treatment for a short period of time, i.e. 7 days, to avoid any long-term
mutagenic effects. For the selection, the LD100 dose (1000µg/ml) of zeocin was used to eliminate
all the untransduced cells (Figure 10).

Dose-Response Curves for Stress Inducing Chemicals
TBHQ was used for inducing oxidative stress and thapsigargin for ER stress. The doseresponse curve for each chemical was performed and the IC50 values for both the drugs was
calculated to be 4.26nM for Thapsigargin and 4.09nM for TBHQ. LD10 (1 nM) and LD20 (2 nM)
doses were selected for treatment in order to introduce cellular stress but avoid avid cell death
(Figure 11).
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Thapsigargin and TBHQ induce increased oxidative stress
Ba/F3 parent cells were treated with increasing doses of TBHQ (1 nM, 2 nM, 5 nM and 10
nM) for 6 hours to induce cellular oxidative stress. ROS production was also determined following
treatment with thapsigargin, a non-competitive inhibitor of sarcoplasmic/endoplasmic reticulum
Ca2+-ATPase (SERCA), which promotes oxidative stress indirectly by inducing UPR. Thapsigargin
leads to decrease in the ER calcium levels, thereby leading to accumulation of excess Calcium in
the cytosol. Without calcium, the calcium-dependent ER chaperones lose their protein folding
activity, thus leading to accumulation of misfolded proteins in the ER. This triggers the increase in
free radicals, leading to oxidative stress conditions.
To estimate the levels of ROS production due to increasing chemical treatment, MitoSOX
and CellROX Green oxidative stress probes were used to label the mitochondrial and cytosolic ROS,
respectively, followed by detection of fluorescence using flow cytometry. The data shown in Figure
12, confirmed that there is an increase in cellular oxidative stress at our selected doses, 1nM and 2
nM for both the chemicals. Extensive cell death was observed at higher doses, i.e. 5 nM and 10 nM.
Furthermore, Thapsigargin was observed to induce comparatively more ROS production than
TBHQ. Also, cytosolic ROS was produced at a more consistent rate as compared to mitochondrial
ROS, which was somewhat erratic.

Thapsigargin treatment also induces ER stress
Ba/F3 cells were treated with three different doses of thapsigargin: 1 nM, 2 nM and 5 nM
for different time intervals (0-48 hours) to study the dose-response and time-dependent effects of
thapsigargin on the ER stress levels. qPCR was performed to measure the levels of UPR markers
Atf4, Atf6, HSPA5 (BiP) GADD153 (Chop), and Xbp1 (Figure 13). Although there was no increase
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observed in the first 8 hours of treatment, a steep increase in all ER stress marker levels occurred
after prolonged treatment (24 hours and 48 hours).

NGS Analysis: New Mutations observed in both treated and untreated samples
No correlation was seen between the treatments with thapsigargin and TBHQ and the total
number of new mutations. NGS analysis showed that although many new mutations were present
in both day 15 and 30 samples, the number of mutations was statistically not different between
treated and untreated samples for the endogenous genes (Csf3r and Runx1). However, in the
exogenous transduced gene (CSF3R), there were a greater number of new mutations in the treated
samples as compared to the untreated controls on days 15 and 30 (Figure 14). The number of
mutations observed in each sample is provided in Appendix Table 3.

GFP region was mutated more than CSF3R
A comparative study was done to study the LFC (Log Fold Change) between the number of mutated
positions relative to the region size for CSF3R and GFP. Surprisingly, for all the samples, the GFP
region was more mutated as compared to the hypothesized hotspot, CSF3R. The number of
mutations calculated were relative to the region size, i.e. 427 bp for CSF3R and 617 bp for GFP.
The p-values for each treatment was calculated and the samples that had significant p-values, i.e. pvalue > 0.05, were represented by triangular markets in Figure 15. The values used to make the plots
are given in Appendix Table 4. The table provides the number of mutations in both CSF3R and GFP
regions, for each sample and treatment. The proportion of mutations with respect to the region size
are also given. These values were used to calculate the LFC proportions.
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Mutational Analysis: Three major trends observed
The mutations observed in all the samples could be categorized into 3 disjoint groups as
represented in Figure 16: the first represent mutations whose frequency increased by 15 days,
followed by diminishing frequency by day 30; the second set represent the mutations for which
frequency increased on day 15 and continued to increase on day 30; and the third set consisted of
mutations that were dormant until day 15 and emerged only at day 30. The first group of mutations
compared to second group, also shows a faster increase in frequency. The values which were used
to plot the graphs are provided in Appendix Table 5. The date is divided into different sets according
to the gene of interest. For each gene, there are further subsets for each treatment viz.: Untreated,
TBHQ 1nM; TBHQ 2 nM; thapsigarging1 nM and thapsigargin 2 nM. For each subset, a histogram
of the log (base 10) of the ratio of altered reads over coverage was developed. Once separated
according to days, the median of each subgroup was calculated and plotted.

Reagent development for future experiments: Clonal Competition between different Ba/F3
mutant cell lines
Ba/F3 cell line was transduced with lentivirus containing ELANE wildtype and ELANE G185R.
Transduction was confirmed using western blotting (Figure 17). Each of these cell lines, were then
transduced with WT and d715 CSF3R, thus leading to 4 different cell lines. Transduced cells were
assessed for GFP expression by FACS (BD LSRFortessa-X20™) to confirm the CSF3R
transduction. Selection of transduced cells was performed using FACS where GFP positive cells
were sorted and untransduced GFP-negative cells were eliminated (Figure 18). Each of the 4 cell
lines were then transduced with lentivirus containing unique barcodes (Table 1). Puromycin
selection was then performed to select the transduced cells. To calculate the lethal dose of
puromycin for Ba/F3 cells, a dose response curve was formulated as shown in Figure 19. The cells
19

were then treated with the lethal dose (LD100) of 3 µg/ml for 7-10 days to select the transduced
cells.
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CHAPTER 4
FIGURES AND TABLES

1.

Figure 1. Maturation block at promyelocyte-myelocyte stage observed in SCN1. Granulopoiesis
begins when the myeloblaöst differentiates into a neutrophilic promyelocyte that is irreversibly
committed to the neutrophilic cell line. Promyelocytes are large cells with purple-staining
nonspecific azurophilic granules. Promyelocytes develop into myelocytes that are characterized by
the presence of smaller specific or secondary granules. Granule production ceases at the end of the
myelocyte stage and the remaining stages are characterized primarily by a reduction in cell size and
a change in nuclear shape. When the nucleus becomes flattened and the chromatin further
condensed, the cell is called a metamyelocyte. When the nucleus becomes horseshoe-shaped, it is
called a mature band cell. The cell is considered a mature neutrophil when the nucleus becomes
segmented into lobes. In SCN patients, there is a maturation arrest in the promyelocytic stage, which
leads to an accumulation of immature granulocytic precursors in the bone marrow. Neutrophil
elastase is expressed at its highest levels in the promyelocytic stage and GCSFR is primarily
expressed in neutrophils, although, some traces of CSF3R expression is also observed in neutrophil
progenitors32.
21

2.

Figure 2. Frequently mutated sites in CSF3R in SCN patients that lead to development of
MDS/AML (figure from Ref. 11). These mutations were most frequently observed in SCN patients
by Germeshausen et al. in 2007 (Blood). Most are nonsense mutations leading to a premature stop
codon. Loss of tyrosine residues is observed in these patients as a result of these truncations.
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3.

Figure 3. Localization of frequently observed mutations in CSF3R Exon 17. The positions of
the frequently observed mutations (shown in Figure 2) found in SCN patients. The codons
highlighted in red undergo truncation mutations. Asterix (*) is placed on the nucleotide that is
replaced to get a mutated stop codon. At each site, indicate the mutation C-, T->. Other mutations
were also observed. The frameshift mutations were seen in Serine (747 position). Deletion of ten
amino acids, highlighted in blue, were also observed in one patient.
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4.

Figure 4. Mutation by tautomeric shifts in the bases of DNA23. (a) In the example diagrammed,
a guanine undergoes a tautomeric shift to its rare enol form (G*) at the time of replication. (b) In its
enol form, it pairs with thymine. (c) and (d) In the next replication, the guanine shifts back to its
more stable keto form. The thymine incorporated opposite the enol form of guanine, seen in (b),
directs the incorporation of adenine in the subsequent replication, shown in (c) and (d). The net
result is a G·C → A·T mutation.
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5.

Figure 5. Plasmid map for transduced partial C-terminal of CSF3R-GFP construct. The
plasmid map shows the transduced construct, which contained the partial C terminal of CSF3R
(purple) fused with the GFP tag (green). The transduced construct is bleomycin and ampicillin
resistant. It also contains the CMV promoter and enhancer region.
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6.

Figure 6. Experimental setup for 30-Day treatment with stress-inducing chemicals. Ba/F3
transduced cells were treated in triplicates for each treatment. Triplicates for untreated control
cells were also harvested in identical conditions.
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7.

Figure 7. NGS was performed in three steps. The first step was to amplify the genomic DNA of
each segment separately for all samples. This was followed by second round of amplification to
introduce sequence adapters for segment identification. This was followed by the final sequencing
in both forward and reverse directions.
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8.

Figure 8. Primer design for the transduce CSF3R-GFP construct. The primers were designed
to allow an overlap between each segment, thus increasing the efficiency of coverage of complete
construct. To validate the primer sequences, PCR was carried out on all samples and the amplicons
were confirmed using Sanger sequencing.
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9.

Figure 9. Plasmid map for Barcode 69 in PlkO.1 vector. Barcodes were transduced into Ba/F3
cells. Each barcode consisted of seven unique nucleotides, with common flanking sequence on both
ends. The plasmid size for each of the barcodes was approximately 7000 bp in size. Each construct
was puromycin and ampicillin resistant.
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10.

Figure 10. Transduction of Ba/F3 cells was confirmed using flow cytometry and selection was
carried out in zeocin. A) Ba/F3 parent cells were transduced with partial C terminal of CSF3R
fused with GFP positive construct. Flow cytometry analysis confirmed the presence of 2 distinct
cell populations: GFP-negative untransduced parent cells (pink) and GFP-positive transduced cells
(Blue). B) Zeocin was chosen as the selection antibiotic. The dose-response curve for zeocin showed
1000 µg/ml to be the LD100 dose which caused 100% cell death.
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11.

Figure 11. Based on the dose-response curves for both the chemicals, we selected n LD10 (1
nM) and LD20 (2 nM) as the stress inducing dosage. MTT assay was performed to calculate the
lethality of each drug. Both Thapsigargin and TBHQ had similar IC50 values (4.26 nM and 4.09
nM respectively). Both chemicals had similar sublethal (LD10 and LD20) doses.
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12.

Figure 12. Dose-response for ROS production by TBHQ and thapsigargin. Mitochondrial and
cytosolic fluorogenic probes (Mitosox and CellRox respectively) were used to measure the cellular
oxidative stress using live cell imaging. Oxidative stress was induced more in the cytosol as
compared to the mitochondria. Also, in general, there was an increase in the stress levels at both 1
nM and 2 nM doses. However, higher doses of 5 nM and 10 nM were much more toxic and lead to
extensive cell death.
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13.

Figure 13. Prolonged thapsigargin exposure leads to increased levels of UPR markers. UPR
marker expression was measured by real-time PCR. Data is normalized to the expression of actin to
get the dCt values. The dCt values were further normalized to the dCt value of day 0 control. All
the UPR markers followed the same trend: decrease in the first 8 hours followed by a rapid increase.
The experiment was repeated 3 times to confirm the findings.
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14.

Figure 14. Accumulation of new mutations during the treatment period. Only CSF3R shows
significant difference in the number of acquired mutations in treated and untreated samples.
Although new mutations did arise during the treatment duration, however there was no correlation
between the treatment and the total number of new mutations, at least in the endogenous systems.
Mutations were observed in both treated and untreated samples for the three genes. In the exogenous
CSF3R, the treated samples had more mutations than the untreated sample. However, in the
endogenous genes, untreated samples had more mutations than treated samples. (A) The plots show
the total number of mutations detected for each sample. Each point corresponds to one replicate, the
bars represent mean +/-standard deviation (sd). The values on the right-Y axis are the p-values from
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a t-test between the mean values of each treated sample (either Thapsigargin or TBHQ) compared
to the untreated samples from the same day. Each color marks different treatment types. (B) These
plots are another graphical representation of the same date represented in Figure 6A.
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15.

Figure 15. Log Fold Change of mutated sites (GFP vs CSF3R). The plot shows the LFC of the
number of mutated positions relative to the region size for GFP vs CSF3R. The values below 0
indicate more mutations in the GFP region. The triangle shaped markers correspond to replicates in
which the difference between the mutation proportions (standard test for 2 proportions) is significant
(unadjusted p value<0.05).
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16.

Figure 16. Three major trends were observed in the mutations that were consistent in all
samples. The first set, represented by blue line, consisted of mutations that were absent until day
15 and arose only on day 30. The second set (red line) consisted of mutations whose frequency
consistently grew during the 30-day period. The third set portrayed by grey line consisted of
mutations whose frequency increased on day 15 followed by a decrease on day 30.
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17.

`
Figure 17. Transduction of WT and G185R ELANE in Ba/F3 cells was confirmed using
Western Blotting. The cells were treated with doxycycline to induce the expression of ELANE.
Negative control, i.e. the parent Ba/F3 cells showed no protein expression after doxycycline
treatment. Human ELANE expression was observed at the expected size (29 kDa) in both
transduced cell lines.
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18.

Figure 18. Flow cytometric confirmation of CSF3R transduction. The cell line population
in black represents GFP negative cells and the population in grey represent GFP positive cells.
The GFP positive cells that were selected by flow cytometric cell sorting are represented in
green. The black population shows the GFP-negative cells, i.e. the untransduced Ba/F3 parent
cells.
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19.
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Figure 19. Puromycin dose-response curve for selection of cells transduced with lentivirus
containing unique barcode. Lethal dose (LD100) was calculated to be 3 µg/ml. MTT assay was
used to calculate the cell viability of cells treated with increasing doses of puromycin. 3 µg/ml dose
of puromycin was observed to 100% cell death. The cells were then selected in 3 µg/ml
concentration of puromycin for 10 days to eliminate the untransduced cells.
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Table 1. The unique barcode sequences transduced in different Ba/F3 cell lines

Each barcode consists of seven unique nucleotide sequences, which are flanked by a common
flanking region on both ends. These unique barcodes were transduced in different cell lines
containing a unique combination of different CSF3R and ELANE mutations (Table 2). After the cell
lines are mixed together and subjected to treatment, these unique barcode sequences will be used to
identify the most proliferative cell line.
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Table 2. Each cell line contains a unique barcode identifier and different combinations of
mutations

Ba/F3 cells were first transduced with wildtype and mutant CSF3R. The 2 cell lines thus
produced, were then further transduced with wildtype and G185R ELANE, thus producing 4 cell
lines with different combination of mutations, shown in this table. Each combination was then
transduced with a unique barcode sequence, which will serve as an identifier.
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CHAPTER 5
CONCLUSIONS
Several clinical studies have demonstrated that leukemia transformation is significantly
higher in SCN patients. The age-adjusted incidence of MDS/AML in SCN patients being treated
with G-CSF is reported as 22%33,34. These clinical data strongly suggest that pharmacological
administration of G-CSF for the treatment of SCN is correlated with the development of
MDS/AML5. According to a study by Severe Chronic Neutropenia International Registry (SCNIR),
21% of SCN patients undergoing G-CSF treatment developed leukemia at one point in their
therapy35. The precise contribution of G-CSF is however uncertain, because there are reports of
MDS/AML arising in patients with SCN prior to the availability of G-CSF36–38. The exact
mechanisms of clonal evolution causing the transition from SCN to MDS/AML remain unknown.
This study was done to estimate the number, timeline, and proliferative advantage of mutations in
lymphoid progenitors under cellular stress conditions.
The bioinformatic analysis of the next generation sequencing data show that there is no
significant increase in the number of mutations due to different cellular stress inducing treatments
in Ba/F3 cells. No significant difference was observed between the number of mutations in the
samples treated under cellular stress conditions and untreated controls. Surprisingly, the transduced
GFP construct, having comparatively low GC content, was more highly mutated as compared to the
GC-rich CSF3R region. Thus, these findings challenge our hypothesis that the partial C terminal of
CSF3R is a hotspot for mutations under oxidative and ER stress. Although the published data are
limited, this conclusion is supported by a recent clinical study that shows the mutational landscape
of the hematopoietic stem cells in SCN patients is similar to the age-matched healthy patients34.
We observed that the mutations could be classified into three disjoint groups: first group
consisted of mutations whose frequency increased by day 15 followed by diminished frequency by
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day 30 (increase, decrease). The second group consisted of mutations that continually increased
during the 30-day treatment period (increase, increase). The third group of mutations was dormant
until day 30 and emerged only on day 30 (dormant, increase). These three trends were consistent for
all the samples. It was also observed that the first group of mutations (increase, decrease) are present
at a higher frequency as compared to the second group (increase, increase). This indicates that the
fast increase in mutations could be affecting the cell growth and viability, thus providing a clonal
disadvantage to these cells. On the other hand, the mutations that are acquired at a slower rate does
not cause cell death, thus giving the cell the time to acquire additional mutations that provide a
clonal advantage to them.
This study strongly suggests the possibility of additional factors other than cellular stress
induced mutagenesis in the transition from SCN to AML. The question that remains unanswered is
why SCN patients with germline ELANE mutations are associated with acquired CSF3R mutations?
This question can probably be answered by the second part of the study, which is focused on the
clonal competition between different mutant CSF3R expressing cell lines. Our study continues. So
far, we have generated cell lines with different combinations of CSF3R and ELANE mutations.
These 4 cell lines will now be mixed together and be subjected to G-CSF treatment. The proliferation
rate of each cell line will be measured by estimating the amount of unique barcode sequences using
targeted deep sequencing. We expect that CSF3R mutations to work in cooperativity of ELANE
mutations to provide a proliferative advantage to the cells. Once we get these results, we can further
analyze the clonal competition between other CSF3R mutant expressing cell lines like d717, d725
and d730.
There are several limitations to the study. Most importantly, the cell line model system that we have
chosen does not express wild-type or mutant ELANE. Although the cell line has its own advantage
of rapid doubling time of 12-14 hours, thereby giving us approximately 45-55 generations during
the treatment period of 30 days. Thus, for a more objective analysis, we should repeat the experiment
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on a myeloid progenitor cell line instead of the lymphoid Ba/F3 cells. To confirm ROS production,
ROS inducing mutagens like hydrogen peroxide will be used as a positive control. Because this
study is limited to the analysis of mutational landscape in three genes, it is possible that stress
induction is causing genomic instability in other genes. The initial cell genotoxicity will be
measured by performing the HPRT-Forward-Mutation-Assay to study the nucleotide oxidation. The
future experiments will be designed for broader sequencing analysis on these samples, either by
performing whole-exome sequencing or targeted deep sequencing for a larger number of genes. We
also aim to sequence at intermediate time intervals to study the trends that have been observed at
day 15 and day 30. We particularly want to focus on day 10 samples, as until then, no selection was
carried due to passaging and thus these sample would contain all the mutations that occurred since
day 0. Current work seeks to measure the clonal competition between different mutant CSF3R and
ELANE expressing cell lines. Since the cell lines have been prepared and single clones have been
isolated, the next step in the study is to treat the cells with G-CSF treatment followed by NGS
analysis to quantify which cell line proliferative advantage over others.
To summarize, our data suggests that in vivo cellular stress induction does not promote the
genomic instability in Ba/F3 cells. We observed no increase in the mutagenesis in cells that were
treated with cellular stress inducing chemicals as compared to untreated samples. Surprisingly, we
observed that the GC-rich region in CSF3R had fewer genomic alterations as compared to the GFP
construct with a considerably low GC content. This study also revealed that slowly acquiring
mutations does not affect the cell viability, thus providing the time for persistence of a clone that
provides proliferative advantage to the cells. Thus, our study is consistent with the conclusion of the
study by Xia et al.34, that both intrinsic and non-intrinsic cellular changes could be responsible for
the development of MDS/AML in SCN patients. However, since CSF3R mutations are specific only
to SCN associated leukemias, it is evident that these acquired mutations are associated with germline
ELANE mutations in SCN. This project lays the groundwork for further understanding the possible
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mechanisms behind the association of germline ELANE and spontaneous CSF3R mutations that may
be responsible for the evolution of MDS/AML from SCN.
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APPENDIX
Table 3. Number of mutations for each sample, for all 3 genes

Group

CSF3R
(Human)

Csf3r
(Mouse)

Sample
Day
DAY15_TBHQ_1nM_A
15
DAY15_TBHQ_1nM_B
15
DAY15_TBHQ_1nM_C
15
DAY15_TBHQ_2nM_A
15
DAY15_TBHQ_2nM_B
15
DAY15_TBHQ_2nM_C
15
DAY15_Tg_1nM_A
15
DAY15_Tg_1nM_B
15
DAY15_Tg_1nM_C
15
DAY15_Tg_2nM_A
15
DAY15_Tg_2nM_B
15
DAY15_Tg_2nM_C
15
DAY15_UNTREATED_A
15
DAY15_UNTREATED_B
15
DAY15_UNTREATED_C
15
DAY30_TBHQ_1nM_A
30
DAY30_TBHQ_1nM_B
30
DAY30_TBHQ_1nM_C
30
DAY30_TBHQ_2nM_A
30
DAY30_TBHQ_2nM_B
30
DAY30_TBHQ_2nM_C
30
DAY30_Tg_1nM_A
30
DAY30_Tg_1nM_B
30
DAY30_Tg_1nM_C
30
DAY30_Tg_2nM_A
30
DAY30_Tg_2nM_B
30
DAY30_Tg_2nM_C
30
DAY30_UNTREATED_A
30
DAY30_UNTREATED_B
30
DAY30_UNTREATED_C
30
DAY15_TBHQ_1nM_A
15
DAY15_TBHQ_1nM_B2
15
DAY15_TBHQ_1nM_C
15
DAY15_TBHQ_2nM_A
15
DAY15_TBHQ_2nM_B
15
DAY15_TBHQ_2nM_C
15
DAY15_Tg_1nM_A
15
DAY15_Tg_1nM_B2
15

Treatment
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_2nM
Tg_2nM
Tg_2nM
UNTREATED
UNTREATED
UNTREATED
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_2nM
Tg_2nM
Tg_2nM
UNTREATED
UNTREATED
UNTREATED
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
Tg_1nM
Tg_1nM
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No. of
Replicate Mutations
A
17
B
16
C
20
A
16
B
18
C
21
A
15
B
20
C
20
A
20
B
18
C
14
A
14
B
14
C
17
A
16
B
23
C
16
A
13
B
16
C
17
A
20
B
22
C
18
A
16
B
20
C
16
A
15
B
15
C
16
A
8
B2
7
C
16
A
15
B
21
C
16
A
20
B2
4

Runx1
(Mouse)

DAY15_Tg_1nM_C
DAY15_Tg_2nM_A2
DAY15_Tg_2nM_B
DAY15_Tg_2nM_C2
DAY15_UNTREATED_A
DAY15_UNTREATED_B
DAY15_UNTREATED_C
DAY30_TBHQ_1nM_A
DAY30_TBHQ_1nM_B
DAY30_TBHQ_1nM_C
DAY30_TBHQ_2nM_A
DAY30_TBHQ_2nM_B
DAY30_TBHQ_2nM_C
DAY30_Tg_1nM_A
DAY30_Tg_1nM_B
DAY30_Tg_1nM_C
DAY30_Tg_2nM_A
DAY30_Tg_2nM_B
DAY30_Tg_2nM_C
DAY30_UNTREATED_A
DAY30_UNTREATED_B
DAY30_UNTREATED_C
DAY15_TBHQ_1nM_A
DAY15_TBHQ_1nM_A
DAY15_TBHQ_1nM_B
DAY15_TBHQ_1nM_B
DAY15_TBHQ_1nM_C
DAY15_TBHQ_1nM_C
DAY15_TBHQ_2nM_A
DAY15_TBHQ_2nM_B
DAY15_TBHQ_2nM_C
DAY15_TBHQ_2nM_C
DAY15_Tg_1nM_A
DAY15_Tg_1nM_A
DAY15_Tg_1nM_B
DAY15_Tg_1nM_B
DAY15_Tg_1nM_C
DAY15_Tg_1nM_C
DAY15_Tg_2nM_A
DAY15_Tg_2nM_A
DAY15_Tg_2nM_B
DAY15_Tg_2nM_B
DAY15_Tg_2nM_C
DAY15_Tg_2nM_C
DAY15_UNTREATED_A

15
15
15
15
15
15
15
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15
15

Tg_1nM
Tg_2nM
Tg_2nM
Tg_2nM
UNTREATED
UNTREATED
UNTREATED
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_2nM
Tg_2nM
Tg_2nM
UNTREATED
UNTREATED
UNTREATED
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_2nM
Tg_2nM
Tg_2nM
Tg_2nM
Tg_2nM
Tg_2nM
UNTREATED
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C
A2
B
C2
A
B
C
A
B
C
A
B
C
A
B
C
A
B
C
A
B
C
A
A
B
B
C
C
A
B
C
C
A
A
B
B
C
C
A
A
B
B
C
C
A

23
8
15
12
16
10
21
8
10
21
40
26
22
10
19
24
31
18
13
19
21
22
3
5
1
7
1
6
5
6
2
7
2
9
3
13
1
11
1
7
1
6
1
5
3

DAY15_UNTREATED_A
DAY15_UNTREATED_B
DAY15_UNTREATED_B
DAY15_UNTREATED_C
DAY15_UNTREATED_C
DAY30_TBHQ_1nM_A
DAY30_TBHQ_1nM_A
DAY30_TBHQ_1nM_B
DAY30_TBHQ_1nM_B
DAY30_TBHQ_1nM_C
DAY30_TBHQ_1nM_C
DAY30_TBHQ_2nM_A
DAY30_TBHQ_2nM_A
DAY30_TBHQ_2nM_B
DAY30_TBHQ_2nM_C
DAY30_TBHQ_2nM_C
DAY30_Tg_1nM_A
DAY30_Tg_1nM_A
DAY30_Tg_1nM_B
DAY30_Tg_1nM_B
DAY30_Tg_1nM_C
DAY30_Tg_1nM_C
DAY30_Tg_2nM_A
DAY30_Tg_2nM_A
DAY30_Tg_2nM_B
DAY30_Tg_2nM_B
DAY30_Tg_2nM_C
DAY30_Tg_2nM_C
DAY30_UNTREATED_A
DAY30_UNTREATED_A
DAY30_UNTREATED_B
DAY30_UNTREATED_B
DAY30_UNTREATED_C
DAY30_UNTREATED_C

15
15
15
15
15
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30
30

UNTREATED
UNTREATED
UNTREATED
UNTREATED
UNTREATED
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_1nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
TBHQ_2nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_1nM
Tg_2nM
Tg_2nM
Tg_2nM
Tg_2nM
Tg_2nM
Tg_2nM
UNTREATED
UNTREATED
UNTREATED
UNTREATED
UNTREATED
UNTREATED
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A
B
B
C
C
A
A
B
B
C
C
A
A
B
C
C
A
A
B
B
C
C
A
A
B
B
C
C
A
A
B
B
C
C

6
3
4
2
6
2
4
2
8
1
25
2
7
6
2
5
1
10
2
15
1
10
1
11
1
5
2
5
2
7
2
5
3
7

Table 4. Log Fold Change (LFC) between number of mutated positions in CSF3R vs GFP
Column 1 gives all the samples being tested. nMut_CSF3R column contains the number of
mutations in the CSF3R region for each sample. Similarly, nMut_GFP contains the number of
mutations in the GFP region, for each sample. Prop_CSF3R and Prop_GFP columns contain the
number of mutations with respect to the size (NO. of mutations/No of base pairs) of CSF3R and
GFP regions, respectively. The unadjusted p-values are provided in the pval column, followed by
the adjusted P values in padj column.

Sample

Day nMut_CSF3R nMut_GFP Prop_CSF3R Prop_GFP PropLFC

DAY15_TBHQ_1nM_A

15

2

15

0.004673

DAY15_TBHQ_1nM_B

15

3

10

0.007009

DAY15_TBHQ_1nM_C

15

6

12

0.014019

DAY15_TBHQ_2nM_A

15

4

16

0.009346

DAY15_TBHQ_2nM_B

15

6

13

0.014019

DAY15_TBHQ_2nM_C

15

3

11

0.007009

DAY15_Tg_1nM_A

15

4

15

0.009346

DAY15_Tg_1nM_B

15

7

13

0.016355

DAY15_Tg_1nM_C

15

5

14

0.011682

DAY15_Tg_2nM_A

15

2

13

0.004673

DAY15_Tg_2nM_B

15

2

14

0.004673

DAY15_Tg_2nM_C

15

6

10

0.014019

DAY15_UNTREATED_A

15

1

13

0.002336

DAY15_UNTREATED_B

15

3

9

0.007009

DAY15_UNTREATED_C

15

6

12

0.014019

DAY30_TBHQ_1nM_A

30

4

13

0.009346
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0.024272 2.376895
0.016181 1.206970
0.019417 0.470004
0.025890 1.470004
0.021036 0.585481
0.017799 1.344473
0.024272 1.376895
0.021036 0.363089
0.022654 0.955431
0.021036 2.170444
0.022654 2.277359
0.016181 0.206970
0.021036 3.170444
0.014563 1.054966
0.019417 0.470004
0.021036 1.170444

pval

padj

0.026682 0.190595
0.301753 0.411481
0.675673 0.750748
0.090750 0.263796
0.548445 0.658134
0.222648 0.351549
0.123105 0.263796
0.753610 0.807440
0.284178 0.405968
0.054341 0.232890
0.038119 0.190595
0.980850 0.980850
0.020668 0.190595
0.405011 0.528276
0.675673 0.750748
0.221909 0.351549

DAY30_TBHQ_1nM_B

30

3

13

0.007009

DAY30_TBHQ_1nM_C

30

6

10

0.014019

DAY30_TBHQ_2nM_A

30

3

13

0.007009

DAY30_TBHQ_2nM_B

30

1

12

0.002336

DAY30_TBHQ_2nM_C

30

2

14

0.004673

DAY30_Tg_1nM_A

30

1

12

0.002336

DAY30_Tg_1nM_B

30

3

13

0.007009

DAY30_Tg_1nM_C

30

5

14

0.011682

DAY30_Tg_2nM_A

30

2

11

0.004673

DAY30_Tg_2nM_B

30

6

14

0.014019

DAY30_Tg_2nM_C

30

4

13

0.009346

DAY30_UNTREATED_A

30

4

13

0.009346

DAY30_UNTREATED_B

30

4

13

0.009346

DAY30_UNTREATED_C

30

3

13

0.007009
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0.021036 1.585481
0.016181 0.206970
0.021036 1.585481
0.019417 3.054966
0.022654 2.277359
0.019417 3.054966
0.021036 1.585481
0.022654 0.955431
0.017799 1.929436
0.022654 0.692396
0.021036 1.170444
0.021036 1.170444
0.021036 1.170444
0.021036 1.585481

0.118481 0.263796
0.980850 0.980850
0.118481 0.263796
0.030164 0.190595
0.038119 0.190595
0.030164 0.190595
0.118481 0.263796
0.284178 0.405968
0.109531 0.263796
0.439479 0.549349
0.221909 0.351549
0.221909 0.351549
0.221909 0.351549
0.118481 0.263796

Table 5. Median of ratio of altered reads over sequencing coverage
For each gene, the date is divided into further subsets, according to treatment type. For each
subset, a histogram of the log (base 10) of the ratio of altered reads over coverage was developed.
Once separated according to days, the median of each subgroup was calculated. These median
values were then plotted in Figure 16.
A. Human CSf3R
Human CSF3R

Day Untreated (0, inc)
0
0
15
0
30
0.000887725

TBHQ 1 (0, inc)
0
15
30

0
0
0.001277289

TBHQ 2 (0, inc)
0
15
30

0
0
0.000687286

Tg 1 (0, inc)
0
15
30

0
0
0.00079911

Untreated
Untreated (inc, inc)

Untreated (inc, dec)
0
0
0.000231289
0.000615185
0.000500624
0.00017998

TBHQ 1 nM
TBHQ 1 (inc, inc)

TBHQ 1 (inc, dec)

0
0.000233828
0.000412307

TBHQ 2 nM
TBHQ 2 (inc, inc)

0
0.000807103
0.00017998

TBHQ 2 (inc, dec)

0
0.000259646
0.000444045

Thapsigargin 1 nM
Tg 1 (inc, inc)

0
0.000669902
0.00017998

Tg 1 (inc, dec)

0
0.000234742
0.000382576

0
0.000577848
0.00017998

Thapsigargin 2 nM
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Tg 2 (0, inc)
0
15
30

0
0
0.001185711

Tg 2 (inc, inc)

Tg 2 (inc, dec)

0
0.000260518
0.000419425

0
0.000521002
0.00017998

B. Mouse Csf3r
Mouse Csf3r

Day Untreated (0, inc)
0
0
15
0
30
0.000518643

TBHQ 1 (0, inc)
0
15
30

0
0
0.000526455

TBHQ 2 (0, inc)
0
15
30

0
0
0.00048037

Tg 1 (0, inc)
0
15
30

0
0
0.000593884

Tg 2 (0, inc)
0
15
30

0
0
0.000626228

Untreated
Untreated (inc, inc)

Untreated(inc, dec)

0
0.000313599
0.000551422

TBHQ 1 nM
TBHQ 1 (inc, inc)

0
0.000995043
0.000358031

TBHQ 1 (inc, dec)

0
0.000253049
0.000762185

TBHQ 2 nM
TBHQ 2 (inc, inc)

0
0.000719266
0.000173521

TBHQ 2 (inc, dec)

0
0.000276113
0.000593368

Thapsigargin 1 nM
Tg 1 (inc, inc)

0
0.000673067
0.000261271

Tg 1 (inc, dec)

0
0.000451671
0.000685648

Thapsigargin 2 nM
Tg 2 (inc, inc)

0
0.000582751
0.00017998

Tg 2 (inc, dec)

0
0.000261467
0.000400772

0
0.001691814
0.00017998
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C. Runx1
Day U (0, inc)
0
0
15
0
30
9.78E-04

Runx1
U (inc, inc)
0
2.22E-04
3.81E-04

U(inc, dec)
0
6.37E-04
8.48E-05

TBHQ 1 (0,
TBHQ 1 (inc,
TBHQ 1 (inc,
Day inc)
inc)
dec)
0
0
0
0
15
0
2.36E-04
9.36E-04
30
1.06E-03
4.68E-04
4.78E-05

TBHQ 2 (0,
TBHQ 2 (inc,
TBHQ 2 (inc,
Day inc)
inc)
dec)
0
0
0
0
15
0
0.000212619
0.000961766
30 0.000544782
0.000348164
0

Day Tg 1 (0, inc)
Tg 1 (inc, inc)
Tg 1 (inc, dec)
0
0
0
0
15
0
2.22E-04
8.82E-04
30
1.04E-03
4.22E-04
4.29E-05

Day Tg 2 (0, inc)
Tg 2 (inc, inc)
Tg 2 (inc, dec)
0
0
0
0
15
0
2.41E-04
6.99E-04
30
7.96E-04
4.11E-04
6.23E-05
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Table 6. Primers for CSF3R, Csf3R and Runx1 used for library preparation of NGS. The
primer sequences were ordered from IDT. Temperature gradient PCR’s were performed to select
the optimum annealing temperature of each primer.

Genoty
pe

Segme
nt
1

CSF3R
(Human
)

2

ACATCAATGGGCGTGGATAG
CCAGCGATCAGGTCCTTTAT
G
CGGCAATCCAAATGATGGTT
AT

TGGAGTCACAGCGGAGATA
CAGGTACTGATGGAAGCCAT
AC

66oC
64oC
62oC

GCTCGTGCTGGCATCTAC

63oC

GACCTCCACCTGCTCCT
ACGTGATAATATCCAGTTGTT
AGGT

66.4oC

4

GGCAACTAACTGCTGGAACT
CTCCGGTAGTAATAAAGGCT
TCTG
GACGGACGGCTCTTCTATAA
AC
TAGGTGTACCAGGAGAACA
AG

GAGAGGTGAGAGAGTTGACC

61.9oC

5

GGGTGAAGGGAGAGGGA

CCCTTAGAGCACCCAGAAAG

72oC

6

ATACTTGGGCTCTAGTGGT

CCTGTGTCTTTCTGTGTCTC

61.5oC

7

CACACACTCATGCCTTCTCTT CATGTTGGTGGGCGAGTT
GCAATCGATAAGGTGCGGAA
CTGCACCAACGCATCCA
A

2
3
4
1
2
3

Runx1
(Mouse)

Reverse Primer (Anti-sense)

CGGCTGGTTCTTCAGATAGTT
GGGTCTTGAATGGAACCAGA
CCAGGCAAGTATGTCCCTTT T
CTCTATGGTCAGGTGCTTGA TTGGGCTGTAAGCAGTATCTA
G
TC
CTTGAAGACCCTGCCCTATT GGCCTCGAACTCAGAAATCTA
C
C
TGGTCACCATTCGTCTTTCAT GAGTCCACTTCTCAAGATCCA
A
C

3
1

Csf3r
(Mouse)

Forward Primer (Sense)

Annealing
Temperatu
re

8
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64oC
64oC
72oC
71.3oC

62.4oC

72oC
65oC
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